微球的最新进展为治疗性干预在骨关节炎中提供了有针对性的治疗
1Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research-Raebareli, Lucknow, India.
Journal of microencapsulation
|July 5, 2024
概括
微球为骨关节炎 (OA) 提供了一个有希望的解决方案,通过改善药物输送到关节. 本综述探讨了这些先进的传递系统如何提高OA管理的治疗疗效.
科学领域:
- 生物材料科学 生物材料科学
- 药物输送系统 药物输送系统
- 类风湿病学 类风湿病学
背景情况:
- 骨关节炎 (OA) 影响全球2.4亿人,目前的治疗只能控制症状,而不是疾病的进展.
- 关节软骨的不良血管系统阻碍了药物的生物可用性,并导致快速消除,使有效的OA治疗复杂化.
- 现有的OA药物,包括KGN和IL-1受体对抗剂,面临着影响其治疗潜力的配方挑战.
研究的目的:
- 审查微球作为药物输送系统的潜力,以有效的骨关节炎 (OA) 管理.
- 探索用于微球中的各种生物材料,用于OA的药物和生物物质的输送.
- 通过有针对性的传递策略,突出显微球在提高治疗疗效方面的作用.
主要方法:
- 针对OA的基于微球的治疗方法的综合文献综述.
- 在微球配方中使用的不同生物材料的分析.
- 检查不同药物输送路径和针对OA干预的向策略.
- 近几十年来对OA中微球应用相关的临床试验的综述.
主要成果:
- 微球具有出色的物理化学特性,适合OA干预.
- 使用微球的准策略可以显著提高OA管理中的治疗疗效.
- 目前正在探索各种生物材料用于微球开发,以克服目前的药物输送限制.
结论:
- 微球代表了一个可行的平台,可以推进OA治疗,而不仅仅是症状管理.
- 优化的微球配方可以提高药物的生物可用性,并延长患病关节的停留时间.
- 需要进一步的研究和临床试验,以充分实现微球在OA的治疗潜力.
相关概念视频
Mesenchymal Stem Cells
4.7K
Mesenchymal stem cells (MSCs) are adult stem cells that can differentiate into most connective tissue cell types, except for hematopoietic cells, depending upon the source of MSCs. For example, bone-marrow-derived MSCs (BM-MSCs) can differentiate into osteocytes, hepatocytes, and pancreatic and neuronal cells. MSCs can be isolated from various sources such as bone marrow, placenta, adipose tissue, teeth, and Wharton’s jelly, a gelatinous substance in the umbilical cord. The ease of their...
4.7K
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K


